Infectious Disease Phase 1 Deal Benchmarks — Japan (2026)

Understanding Infectious Disease Deal Benchmarks at Phase 1

Phase 1 Infectious Disease licensing deals in Japan territory command a median upfront payment of $15M, with values ranging from $7M at the low end to $22M for premium assets. These benchmarks reflect the risk-adjusted value of clinical-stage assets in the infectious disease therapeutic area, where development costs, competitive dynamics, and market potential all factor into deal pricing.

Total deal values — including milestones for development, regulatory, and commercial achievements — range from $54M to $126M, with a median of $90M. Royalty rates for infectious disease assets at this stage typically fall between 2.7% and 5.4% of net sales, reflecting the balance between licensor value contribution and licensee commercialization investment.